China Traditional Chinese Medicine Holdings Co. Limited
CHIZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.38 | 0.16 | -0.37 | 0.49 |
| FCF Yield | 16.77% | 4.43% | 3.32% | -0.56% |
| EV / EBITDA | 8.17 | 6.85 | 8.78 | 4.61 |
| Quality | ||||
| ROIC | 0.15% | 5.30% | 3.04% | 7.78% |
| Gross Margin | 47.59% | 51.18% | 50.32% | 62.09% |
| Cash Conversion Ratio | 15.84 | 0.95 | 1.30 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.90% | -1.66% | -1.14% | 9.98% |
| Free Cash Flow Growth | 204.51% | 20.37% | 796.19% | 92.07% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.84 | 0.92 | 0.60 |
| Interest Coverage | 1.42 | 7.17 | 4.82 | 12.40 |
| Efficiency | ||||
| Inventory Turnover | 1.81 | 1.48 | 1.18 | 1.43 |
| Cash Conversion Cycle | 291.72 | 317.42 | 407.65 | 316.64 |